NeuroMab™ Anti-EGFR BBB Shuttle Antibody(NRZP-1022-ZP3833)

Product Overview

Description

Brain uptake of therapeutic antibodies is severely limited by their size. To achieve enhanced BBB crossing, Creative Biolabs developed a BBB shuttle antibody platform by utilizing the endogenous macromolecule transportation pathway, known as receptor-mediated transcytosis (RMT). The engineered antibody-based carrier is believed to significantly to increase the macromolecule brain entry to combat CNS diseases.
Notes: The BBB antibody is made-to order and available in a customized format. Please don't hesitate contact us for more details.

Species Reactivity

Human

Clonality

Monoclonal

Host Species

Mouse

Applications

Inhib; In Vitro; WB; In Vivo

Relevant Diseases

Alzheimer's Disease; Pain; Multiple Sclerosis

Product Properties

Storage

Store at -20°C. Do not aliquot the antibody.

Research Use Only

For research use only

Target

EGFR

Official Name

EGFR

Full Name

Epidermal Growth Factor Receptor

Alternative Names

Epidermal Growth Factor Receptor; Receptor Tyrosine-Protein Kinase ErbB-1; Erb-B2 Receptor Tyrosine Kinase 1; Proto-Oncogene C-ErbB-1; EC 2.7.10.1; ERBB1; ERBB; HER1; Epidermal Growth Factor Receptor (Avian Erythroblastic Leukemia Viral (V-Erb-B) Oncogene Homolog); Erythroblastic Leukemia Viral (V-Erb-B) Oncogene Homolog (Avian);

Product Pictures

FuncS

Figure 1 shows that human anti-EGF-r antibodies inhibit the binding of EGF to human epidermoid carcinoma A431 cells in vitro, where (□) describes the results of mouse monoclonal antibody 225, and (○) describes the results of mouse monoclonal antibody 528 , (▾) depicts the results obtained with the E1.1 antibody and (▴) depicts the results obtained with the E2.4 antibody.

FuncS

Figure 2 shows that human anti-EGF-r antibodies inhibit the binding of TGF-α to human epidermoid carcinoma A431 cells in vitro, where (□) depicts the results obtained with mouse monoclonal antibody 225, and (♦) depicts the results obtained using E6 Results for the2 antibody, (●) depicts the results obtained with the E6.3 antibody (▴) depicts the results obtained with the E7.2 antibody.

FuncS

Figure 3 shows data related to the inhibition of epidermoid carcinogenesis in nude mice by using human anti-EGF-r antibody in vivo, showing tumor incidence at day 19.

FuncS

Figure 4 shows data related to the inhibition of epidermoid carcinogenesis in nude mice by using human anti-EGF-r antibody in vivo, showing tumor incidence at day 120.

Publications